CAMP4 Therapeutics Corporation (CAMP) vs Keros Therapeutics, Inc. (KROS)
A side-by-side comparison of CAMP4 Therapeutics Corporation and Keros Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CAMP
CAMP4 Therapeutics Corporation
$3.96HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
KROS
Keros Therapeutics, Inc.
$11.01HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CAMP vs KROS
growth of $100 · dividends reinvested · last 2yCAMP -62.6% (-38.8%/yr)KROS -80.1% (-55.4%/yr)CAMP compounded faster over this window
CAMP KROS
CAMP vs KROS: by the numbers
- •CAMP is the larger company ($249M vs $218M market cap).
- •Both run net losses; KROS's is the smaller (-553.88% vs -2543.74% net margin).
- •KROS grew revenue faster over the past five years (172.50% vs -57.68% CAGR).
Metrics side by side
Valuation
| Metric | CAMP | KROS |
|---|---|---|
| P/S ratio | 58.94 | 14.54 |
| P/B ratio | N/A | 0.83 |
Profitability
| Metric | CAMP | KROS |
|---|---|---|
| Gross margin | 53.14% | 94.68% |
| Operating margin | -1488.31% | 28.94% |
| Net margin | -2543.74% | -553.88% |
| ROE | N/A | -31.70% |
| ROIC | -69.76% | -36.49% |
Growth (annualized)
| Metric | CAMP | KROS |
|---|---|---|
| Revenue CAGR (5Y) | -57.68% | 172.50% |
| Total return CAGR (5Y) | N/A | -21.98% |
Frequently asked
- Which has grown faster, CAMP or KROS?
- Over the past five years, KROS grew revenue faster — CAMP at a -57.68% CAGR versus KROS at 172.50%.
Go deeper
Dig into the metrics
CAMP4 Therapeutics ROEKeros Therapeutics ROECAMP4 Therapeutics operating marginKeros Therapeutics operating marginCAMP4 Therapeutics revenue growthKeros Therapeutics revenue growthCAMP4 Therapeutics free cash flowKeros Therapeutics free cash flow
CAMP4 Therapeutics & Keros Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.